140 related articles for article (PubMed ID: 3136954)
1. Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system.
Eisenberg PR; Sobel BE; Jaffe AS
Circulation; 1988 Sep; 78(3):592-7. PubMed ID: 3136954
[TBL] [Abstract][Full Text] [Related]
2. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation.
Eisenberg PR; Sherman LA; Tiefenbrunn AJ; Ludbrook PA; Sobel BE; Jaffe AS
Thromb Haemost; 1987 Feb; 57(1):35-40. PubMed ID: 3109058
[TBL] [Abstract][Full Text] [Related]
3. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
[TBL] [Abstract][Full Text] [Related]
4. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
Weitz JI; Leslie B; Ginsberg J
J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
[TBL] [Abstract][Full Text] [Related]
5. Fibrin-specific thrombolytic agents.
Collen D
Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
[TBL] [Abstract][Full Text] [Related]
6. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
Weitz JI
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
[TBL] [Abstract][Full Text] [Related]
7. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion.
Holvoet P; Lijnen HR; Collen D
Blood; 1986 May; 67(5):1482-7. PubMed ID: 3083892
[TBL] [Abstract][Full Text] [Related]
8. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
9. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor.
Sakata Y; Eguchi Y; Mimuro J; Matsuda M; Sumi Y
Blood; 1989 Dec; 74(8):2692-7. PubMed ID: 2510836
[TBL] [Abstract][Full Text] [Related]
10. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
12. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF
Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E.
Stewart RJ; Fredenburgh JC; Weitz JI
J Biol Chem; 1998 Jul; 273(29):18292-9. PubMed ID: 9660794
[TBL] [Abstract][Full Text] [Related]
15. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
[TBL] [Abstract][Full Text] [Related]
16. Fibrin metabolism in patients with acute myocardial infarction during and after treatment with tissue-type plasminogen activator.
Ring ME; Butman SM; Bruck DC; Feinberg WM; Corrigan JJ
Thromb Haemost; 1988 Dec; 60(3):428-33. PubMed ID: 2976994
[TBL] [Abstract][Full Text] [Related]
17. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction.
Lawler CM; Bovill EG; Stump DC; Collen DJ; Mann KG; Tracy RP
Blood; 1990 Oct; 76(7):1341-8. PubMed ID: 2119827
[TBL] [Abstract][Full Text] [Related]
18. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
19. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
20. The importance of antibody specificity in measuring cross-linked fibrin degradation products by ELISA.
Eisenberg PR; Rylatt DB; Rusticali F; Ferrini D; Ottani F; Galvani M
Blood Coagul Fibrinolysis; 1997 Mar; 8(2):105-13. PubMed ID: 9518041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
